These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18519765)

  • 21. ARE-I polymorphism on PSA gene in prostate cancer patients of a Turkish population.
    Kalay E; Ergen A; Narter F; Agaçhan B; Görmüs U; Yigit N; Isbir T
    Anticancer Res; 2009 Apr; 29(4):1395-8. PubMed ID: 19414393
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
    Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
    J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpressing leptin genetic polymorphism (-2548 G/A) is associated with susceptibility to prostate cancer and risk of advanced disease.
    Ribeiro R; Vasconcelos A; Costa S; Pinto D; Morais A; Oliveira J; Lobo F; Lopes C; Medeiros R
    Prostate; 2004 May; 59(3):268-74. PubMed ID: 15042602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of polymorphism on prostate specific antigen gene on the risk, tumor volume and pathological stage of prostate cancer.
    Chiang CH; Chen KK; Chang LS; Hong CJ
    J Urol; 2004 Apr; 171(4):1529-32. PubMed ID: 15017213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensity of androgen and epidermal growth factor receptor immunoreactivity in samples of radical prostatectomy as prognostic indicator: correlation with clinical data of long-term observations.
    Schäfer W; Funke PJ; Kunde D; Rausch U; Wennemuth G; Stützer H
    J Urol; 2006 Aug; 176(2):532-7. PubMed ID: 16813883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
    Studer UE; Whelan P; Albrecht W; Casselman J; de Reijke T; Hauri D; Loidl W; Isorna S; Sundaram SK; Debois M; Collette L
    J Clin Oncol; 2006 Apr; 24(12):1868-76. PubMed ID: 16622261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.
    Cussenot O; Azzouzi AR; Bantsimba-Malanda G; Gaffory C; Mangin P; Cormier L; Fournier G; Valeri A; Jouffe L; Roupret M; Fromont G; Sibony M; Comperat E; Cancel-Tassin G
    Clin Cancer Res; 2008 Sep; 14(17):5635-9. PubMed ID: 18765558
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
    Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
    J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The association between measures of progression and survival in castrate-metastatic prostate cancer.
    Scher HI; Warren M; Heller G
    Clin Cancer Res; 2007 Mar; 13(5):1488-92. PubMed ID: 17332293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer.
    Spindler KL; Nielsen JN; Ornskov D; Brandslund I; Jakobsen A
    Acta Oncol; 2007; 46(8):1113-7. PubMed ID: 17851837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms of prostate cancer progression to androgen independence.
    McPhaul MJ
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):373-88. PubMed ID: 18471793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
    Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
    J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome.
    Ricciardelli C; Sakko AJ; Stahl J; Tilley WD; Marshall VR; Horsfall DJ
    Prostate; 2009 May; 69(7):761-9. PubMed ID: 19189303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug insight: role of the androgen receptor in the development and progression of prostate cancer.
    Taplin ME
    Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. No association between EGF gene polymorphism and gastric cancer.
    Goto Y; Ando T; Goto H; Hamajima N
    Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2454-6. PubMed ID: 16214932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between FAS polymorphism and prostate cancer development.
    Lima L; Morais A; Lobo F; Calais-da-Silva FM; Calais-da-Silva FE; Medeiros R
    Prostate Cancer Prostatic Dis; 2008; 11(1):94-8. PubMed ID: 17667965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGF promoter SNPs, plasma EGF levels and risk of breast cancer in Chinese women.
    Wang Y; Tian T; Hu Z; Tang J; Wang S; Wang X; Qin J; Huo X; Gao J; Ke Q; Jin G; Ma H; Wang X; Shen H
    Breast Cancer Res Treat; 2008 Sep; 111(2):321-7. PubMed ID: 17940864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.